Effect Of Pippali Rasayana After Koshthashodhana Compared To Kanchnar Guggulu After Koshthashodhana In The Patients Of Hypothyroidism ( Medoroga) Who Already Taking Thyroxine

Add On Effect Of Pippali Rasayana Over Kanchnar Guggulu After Koshthashodhana In Hypothyroidism ( Medoroga ) On Thyroxine - A Comparative Clinical Trial - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/09/073946

Enrollment

Registered

2024-09-17

Start date

Unknown

Completion date

Unknown

Last updated

2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical Health Condition 2: E018- Other iodine-deficiency related thyroid disorders and allied conditions Health Condition 3: E018- Other iodine-deficiency related thyroid disorders and allied conditions

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patients between the age group of 21-50 years of either sex. 2) BMI between 18.5 -29.5 Kg Per M2. 2) Patients of Primary Hypothyroidism with TSH levels more than or equal to 8 mIU L to less than or equal to 30 mIU L with thyroxine (constant dose) 3) Patients having Pratyatma Lakshan of Medoroga. OR 4) Patients having clinical symptoms of hypothyroidism like - Weakness, Fatigue, Muscle ache, Muscle weakness, Breathlessness, Lethargy, Hoarseness of voice, loss of libido, Menstrual abnormality, Puffiness of the face and eyelids, Peripheral edema, Weight gain, Dry coarse skin, Constipation, Hair loss, Feeling cold.

Exclusion criteria

Exclusion criteria: 1) Patient having TSH level higher than 30 mIU L. 2) Recent thyroid surgery or radio-iodine (within 12 months). 3) Diabetes Mellitus patients with uncontrolled hyperglycaemia (FBS more than 200 mg dl and or PPBS more than 300 mg dL and or RBS more than 300 mg dL) 4) Patients with poorly controlled Hypertension (more than 160 100 mm of Hg) 5) Prior clinical diagnosis of dementia. 6) Recent acute coronary syndrome, including myocardial infarction or unstable angina. 7) Plan to move out of the region in which the trial is being conducted within the next 2 years (proposed minimum time of study) 8) Suffering from diseases like HIV, tuberculosis, encephalopathy, goiter, other endocrine disorders and other autoimmune disorders. 9) Pregnancy, lactation. 10) Any other condition medication which interfere with the intervention.

Design outcomes

Primary

Measure	Time frame
Improvement in Thyroid profile and sing and symptoms of Hypothyroidism (Medoroga).Timepoint: Baseline 6 Weeks And Follow Up.	—

Secondary

Measure	Time frame
1) Improvement in Anthropometric measurements. ( BMI Skin Fold Thickness Waist Hip Ratio) 2) Improvement in Lipid profile. 3) Overall improvement in health-related quality of life.(SF 36) Timepoint: Baseline 6 Weeks And Follow Up	—

Countries

India

Contacts

Public ContactDr Jonah S

All India Institute Of Ayurveda

jonahdr@gmail.com8589805246

Outcome results